Reveal the Effect of Mechanical Stretch on Virus‐Cell Membrane Fusion Based on a Microfluidic Chip
Brief intro:
- Author: Canlin Hong, Wan He, Yanhong Wang, Mengying Niu, Gaizhen Kuang, Qingfei Zhang, Fangfu Ye, Yan Zu
- Journal: Advanced Healthcare Materials
- Doi: https://www.doi.org/10.1002/adhm.202505664
- Publication Date: 2026/4/15
Abstract
Lung-on-a-chip models are important for studying the onset and progression of respiratory diseases. However, existing lung chips often lack the ability to precisely regulate alveolar stretch deformation and rarely apply the 3D physiological microenvironment of alveoli to respiratory virus research. Here, we present a biomimetic 3D microfluidic chip microphysiological system for alveolar cells stretch visualization and investigate the effect of mechanical stretch on viral infection. We utilize a SARS-CoV-2 pseudovirus to infect alveolar epithelial cells cultured on the lung alveolus chip. Subsequently, we subjected the cells to varying degrees of mechanical stretch through membrane pressure deformation to examine the impact of these forces on viral invasion. Our study demonstrates that mechanical stretch can attenuate the fluorescence intensity of cytoskeletal proteins and regulate cytoskeletal protein rearrangements, which reduces cell membrane tension and thus virus-membrane fusion on the microfluidic chip for type II alveolar cells. The above features and results show that this chip has an extremely wide range of applications in cellular biomechanical testing, exploration of lung disease mechanisms, and clinical disease treatment.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.